Kredent.com

May 04, 2012
Domestic News
Market Roundup
 Piramal Healthcare Q4FY12 Consolidated YoY Net Loss at Rs 39 crore vs Indian Market
 Pantaloon Retail Board approves issue of 81.6 lakh shares to Bennett & Nifty Oil min to RIL -to disallow USD457 m of cost recovery for 2010-11, to disallow USD778 m of cost recovery in 2011-12. RIL received notice on Wednesday, RIL fined Rs 6600 crore for KG D6 output fall Asian Market
Cipla Gets US FDA tentative nod for HIV-1 drug Viramune generic. Cuts price of Generic Version Bayer’s cancer drug Nexavar prices by 75%  Cairn India to invest USD5 billion in Barmer block to increase output  Delhi High Court adjourns hearing in IGL vs PNGRB matter to May 8  Dr Reddys gets US nod for osteoporosis drug Boniva 150 mg generic  Pheonix Mills board clears raising Rs 1000 crore via QIP route US & Europe
 Bosch to invest Rs 300 crore in Nashik plant expansion  Mcnally Bharat Engineering receives 2 Orders worth Rs.177 crore from NTPC Nasdaq and Unitech Hi-Tech (NTPC Thermal Project worth Rs 170 crore)  GAAR may be put off by a year, tax amt of Rs 10-15 crore may be the threshold FTSE 100  Taib Bank investment in Anantraj Industries could come under scanner of ED & CAC 40 International News
Commodities
 European Central Bank President Mario Draghi left open the option of further Gas (USD/MMBtu) stimulus if the economy continues to deteriorate as investors await the outcome  U.K. commercial property values declined by 0.7% in the first three months of Copper (USD/lb) 2012, the second consecutive quarter of decline  The European Central Bank held interest rates at 1% and will resist calls to do Baltic Dry Index more to fight the euro zone crisis, putting the onus on governments to foster growth and head off anger over austerity policies Currency
Fund Flow
ADR Value

[email protected]
+91-33-40002461/62
Kredent Research Advisors Please see the disclosures on the last page For Private Circulation Only
Sectoral Performance
One Day Change
Five Day Change
* Based on Kredent Proprietary Sectoral Index Q4FY12 Result Estimation
Net Sales (Rs. Crore)
Net profit (Rs. Crore)
Company Name
Expected
Expected
Dividends
Dividend
Record/B.C Date
F&O Scrips
Cash Scrips
Buy Back Open Offer
% of Paid Up
Kredent Research Advisors For Private Circulation Only
Forthcoming Board Meetings
F&O Scrips
Housing Development Finance Corporation Limited Cash Scrips
The United Nilgiri Tea Estates Company Limited Kesar Terminals & Infrastructure Limited Kredent Research Advisors For Private Circulation Only
NIFTY 50 Top Gainers
NIFTY 50 Top Losers
NSE Top Turnover - By Value (in millions)
NSE Top Turnover - By Contracts (in millions)
Turnover
Turnover
Most Active Calls - By Contracts
Most Active Puts - By Contracts
Strike Price
Expiry Date
Strike Price
Expiry Date
BSE SMALLCAP Upper Circuit
BSE SMALLCAP Lower Circuit
Kredent Research Advisors For Private Circulation Only
DISCLOSURES:
This document was produced by Kredent Research Advisors Private Limited ‘Kredent’. The document is being furnished to Kredent clients for their information purposes only and is not an offer or the solicitation of an offer, to buy or sell a security. This document is not to be relied upon or used in substitution for the exercise of independent judgment. Information and opinions contained herein have been compiled or arrived by Kredent from sources believed to be reliable, but Kredent has not independently verified the contents of this document. Accordingly, no representation or warranty, express or implied, is made as to and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this document. Kredent accepts no liability for any loss arising from the use of this document or its contents or otherwise arising in connection therewith. We and our affiliates, directors, and employees worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company (ies) discussed herein or have other potential conflict of interest with respect to any recommendation and related information and opinions. It is being furnished to Kredent clients for their information purposes only and may not be reproduced or published in any media, website or otherwise, in part or as a whole, without the prior consent in writing of Kredent. Persons who receive this document should make themselves aware of and adhere to any such restrictions. ADDRESS:
# 3, Pretoria Street, Kolkata – 700071 For further queries you can ask us at [email protected]
Kredent Research Advisors For Private Circulation Only

Source: http://www.kredent.com/reports/morning_daily_2012_05_04.pdf